Adjunct Laser Therapy in COVID-19 Clinical Pilot Trial

Dr. Scott Sigman, Founder and CMO of OrthoLazer and Team Physician at UMASS Lowell, discusses the publication of a second case report demonstrating positive outcomes for a COVID-19 patient treated with adjunct laser therapy. The patient is part of a randomized clinical pilot trial. The treatment is once-daily for four days using an FDA-cleared laser. Photobiomodulation Therapy is known to have anti-inflammatory effects and in this case study it helped treat the patients’ respiratory symptoms.Dr. Sigman is looking to expand this work and raise awareness among other healthcare providers for this novel therapeutic option.

Dr. Scott A. Sigman is a board-certified orthopedic surgeon specializing in Sports Medicine. He is Founder and Chief Medical Officer of OrthoLazer in MA, a Surgeon at Orthopedic Surgical Associates of Lowell, and a Team Physician at UMASS Lowell. Dr. Sigman is also a Fellow of the World Society of Sports and Exercise Medicine and a Fellow of the Royal College of Surgeons In Ireland. He received his medical degree from the University of Maryland School of Medicine. Dr. Sigman has contributed to numerous publications and research studies regarding advances in the field of orthopedic surgery. He also gives presentations, lectures, and instructional courses to fellow surgeons throughout the world on new shoulder and knee surgery techniques. Most recently, Dr. Sigman started an investigational study on the use of photobiomodulation therapy on COVID-19-induced pneumonia patients.